期刊
MOLECULAR THERAPY-ONCOLYTICS
卷 3, 期 -, 页码 -出版社
CELL PRESS
DOI: 10.1038/mto.2016.11
关键词
-
资金
- NCI NIH HHS [P30 CA008748] Funding Source: Medline
- NICHD NIH HHS [K12 HD028820] Funding Source: Medline
T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, on target/off tumor recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据